Buy — Pfizer Stock

: To offset the loss of exclusivity (LOE) on blockbusters like Eliquis and Ibrance, Pfizer is aggressively reinvesting in oncology and obesity. Key 2026 catalysts include the start of 20 pivotal clinical trials , notably in the high-growth GLP-1 (obesity) market and next-generation cancer therapies. Key Risks and Headwinds

For , Pfizer may remain a "dead money" asset due to the lack of immediate revenue drivers. However, for long-term value and income investors , the stock offers a rare combination of a high, sustainable yield and the potential for a significant "re-rating" once the market gains confidence in its post-2028 growth engine. buy pfizer stock

: The success of Pfizer's $43 billion Seagen acquisition and its internal obesity assets is critical. Any setbacks in late-stage trials or slower-than-expected integration of new assets could further delay the "growth inflection" point, currently estimated for 2028 or 2029 . Summary of Analyst Outlook Metric / Sentiment Consensus Rating Moderate Buy / Hold Average Price Target ~$28.48 to $29.42 Dividend Yield 6.37% – 6.51% 2026 EPS Guidance $2.80 – $3.00 : To offset the loss of exclusivity (LOE)

As of April 2026, the case for buying Pfizer (PFE) stock centers on its status as a "deep value" play with a high dividend yield, contrasted against significant mid-term revenue headwinds. Following its late-2025 financial guidance, which projected flat to slightly declining revenue for 2026, the stock has traded at a significant discount to its historical norms and the broader S&P 500. However, for long-term value and income investors ,

The market currently views Pfizer through the lens of its "COVID hangover" and an impending "patent cliff." However, for long-term investors, the current valuation may represent an attractive entry point based on three primary pillars:

: Pfizer anticipates a $1.5 billion revenue headwind in 2026 due to patent expirations, with these losses projected to accelerate to over $6 billion annually by 2028 .